Back to Results
EGF Analysis in Patients with Plasma Cell Diseases
||Epideermal Growth Factor (EGF) Analysis in Patients with Plasma Cell Diseases
Hematologic Disorders, Renal Disease
||Raymond Comenzo, MD
The purpose of this study is to perform interval urine analyses in patients with plasma cell diseases to determine if epidermal growth factor (EGF) can serve as a clinically useful indicator of kidney function over time in this patient population. This study will enroll 100 plasma cell disease patients over 2 years. No additional visits for this study are required. Patients will make interval donations of first morning urine samples that coordinate with standard follow-up clinic visits to Tufts Medical Center. The patient will bring their first morning urine to Tufts Medical Center in provided container, and the study team will bring the sample to the laboratory for EGF analysis.
- Patients with diagnoses plasma cell disease which include: solitary plasmacytoma, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), mutliple myeloma (MM), light chain amyloidosis (AL), POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes), Waldenstrom's Macroglobulinemia (WM), light chain deposition disease (LCDD) paraproteinemia, and heavy-chain disease.
- Must be willing to make donations of first morning urine.
- Patients who do not have a diagnoses plasma disease (including patients with non-AL amyloidosis).
- Not willing to make donations of first morning urine
Participants will be required to donate first morning urine samples at various intervals depending on their regular follow-up schedule. Participants will be provided with a urine container before each donation. and no donation will be required if the participant is not already planning a visit to Tufts Medical Center for standard of care reasons. No other procedures are required as part of this study.